ClinicalTrials.gg
CompletedNCT00298194Updated Jan 14, 2009

The Effects of Z-338 in Subjects With and Without Functional Dyspepsia

A Phase 2 interventional study of Z-338 in Dyspepsia, sponsored by Zeria Pharmaceutical. Completed at 1 site in Australia. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-01-14.

Sponsored by Zeria Pharmaceutical · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies testing Z 338 in Dyspepsia — 1 open to participants now, 1 under way, none of them phase 3. Z 338 · Dyspepsia.

Planned enrollment
10th of 11
52 · median 282
Started
2006
with 2 others
Phase 2
5 of 11
none open now
Registered
2nd of 11
by date
Lead sponsor
7 of 11
Zeria Pharmaceutical

Among the 11 studies testing Z 338 in Dyspepsia, this one is the 10th largest by planned enrollment, is one of 3 that started in 2006, is one of 5 in phase 2, and was the 2nd registered.

Dyspepsia

372 studies on the registry are indexed under Dyspepsia; 66 are open to participants now.

Browse Dyspepsia studies →

Open to participants now

1 of the 11 studies testing Z 338 in Dyspepsia is open now. Recruiting first, the newest first:

About Z 338

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 46 Dyspepsia studies recruiting now, 16 (35%) set no upper age limit and 23 (50%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing Z 338 in Dyspepsia, or all of them as a file.
02

Study summary

To assess in subjects with and without functional dyspepsia the effects of Z-338 on:

  1. Type and severity of symptoms a standardized nutrient challenge
  2. The gastric nutrient distribution and gastric emptying of a standardized nutrient challenge
  3. The association of the above with the manifestations of symptoms and symptom pattern
03

Conditions studied

  • Dyspepsia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  1. Subjects with functional dyspepsia Positive documented diagnosis of FD via RomeII criteria and three or more moderate symptoms of Gastrointestinal Score
  2. Subjects with no history of functional dyspepsia Clinical assessment, physical examination and laboratory testing without evidence for relevant abnormality.

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
52 participants (estimated)

Interventions

06

Study locations

1 site
  • Royal Adelaide Hospital
    Adelaide, South Australia 5000, Australia
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006 and a primary completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2006
First posted
Mar 1, 2006
Start
Feb 2006
Primary completionActual
Jul 2008
Last update
Jan 14, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00298194
First posted
Mar 1, 2006
Start date
Feb 2006
Primary completion
Jul 2008
Last update
Jan 14, 2009

Study contacts

Gerald Holtmann, Professor
principal investigator · Royal Adelaide Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Z 338

Start the discussion